Veracyte
VCYT on Nasdaq. Medical laboratories. Market value $3.8bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $4.62 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 52 of 100. Price score: 60 of 100. Our list needs 70 on quality and 60 on price.
$44.65 a share, 52% above its 1-year low
Over the past year the price has ranged from $29.45 to $60.91.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $220m | $297m | $361m | $446m | $517m |
| Operating margin | |||||
| Operating margin | -37.3% | -13.9% | -23.8% | 3.6% | 11.2% |
| Debt to equity | |||||
| Debt to equity | 0.00 | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.07bn | 0.07bn | 0.08bn | 0.08bn | 0.08bn |
Health checks
- Free cash flow positive3 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- DebtUnknown
- Revenue growth, five yearsStrong, 34.5% a year
- Buying back its own sharesNo, 12% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $150 million last quarter, up 15% on a year ago.
- Profit: $25 million, after a loss of $980,000 a year ago.
- It keeps 19 cents of each $1 of sales as operating profit, up from 3 cents a year earlier.
- Spare cash over the past 12 months: $166 million, up from $84 million.
- 5% more shares than a year ago. Each share owns a bit less of the company.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $116m |
| December 2024 | $119m |
| March 2025 | $114m |
| June 2025 | $130m |
| September 2025 | $132m |
| December 2025 | $141m |
| March 2026 | $139m |
| June 2026 | $150m |
| Quarter to | Amount |
|---|---|
| September 2024 | $15m |
| December 2024 | $5m |
| March 2025 | $7m |
| June 2025 | -$980,000 |
| September 2025 | $19m |
| December 2025 | $41m |
| March 2026 | $29m |
| June 2026 | $25m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 26 February 2026
- Next quarterly (estimated, 10-Q)
- 30 October 2026
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 370 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Gotham Asset ManagementJoel Greenblatt | $1m | <0.1% | Cut |
Largest holders overall
- BlackRock$792mAdded
- FMR$452m
- Artisan Partners Limited Partnership$325m
- Vanguard Portfolio Management$277mAdded
- State Street$276mCut
- Vanguard Capital Management$211m
- Dimensional Fund Advisors LP$166m
- First Trust Advisors LP$147mAdded
- ARK Investment Management$135mCut
- Wellington Management Group LLP$134mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
8 investors own more than 5%.
- BlackRock, Inc.Passive investor15.2%+6.8 ptsSince 31 July 2025
- FMR LLCPassive investorat least 10.1%+0.4 pts(filed with 1 related holder)Since 29 May 2026
- Artisan Partners Limited PartnershipPassive investorat least 6.9%−1.0 pts(filed with 3 related holders)Since 31 March 2026
- STATE STREET CORPORATIONPassive investor6.3%+1.0 ptsSince 31 March 2026
- Vanguard Portfolio ManagementPassive investor5.7%Since 31 March 2026
- Vanguard Capital ManagementPassive investor5.2%Since 31 March 2026
- ARK Investment Management LLCPassive investorat least 4.9%−0.8 pts(filed with 1 related holder)Since 31 December 2025
- Wellington Management Group LLPPassive investorat least 4.4%(filed with 2 related holders)Since 30 June 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 15.2%+6.8 pts | 31 July 2025 | |
FMR LLC Passive investor | at least 10.1%+0.4 pts (filed with 1 related holder) | 29 May 2026 | |
Artisan Partners Limited Partnership Passive investor | at least 6.9%−1.0 pts (filed with 3 related holders) | 31 March 2026 | |
STATE STREET CORPORATION Passive investor | 6.3%+1.0 pts | 31 March 2026 | |
Vanguard Portfolio Management Passive investor | 5.7% | 31 March 2026 | |
Vanguard Capital Management Passive investor | 5.2% | 31 March 2026 | |
ARK Investment Management LLC Passive investor | at least 4.9%−0.8 pts (filed with 1 related holder) | 31 December 2025 | |
Wellington Management Group LLP Passive investor | at least 4.4% (filed with 2 related holders) | 30 June 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 11 sold $21m, $19m of it under preset trading plans.
- Leite JohnGlobal Chief Commercial OffSoldunder a preset trading plan
- Date
- 21 September 2026
- Shares
- 4,015
- Price
- $40.00
- Value
- $160,600
- Holstein JensDirectorSoldunder a preset trading plan
- Date
- 14 September 2026
- Shares
- 5,000
- Price
- $40.95
- Value
- $204,747
- McGuire AnnieEVP, General CounselSoldunder a preset trading plan
- Date
- 4 September 2026
- Shares
- 3,254
- Price
- $43.09
- Value
- $140,212
- Chambers RebeccaChief Financial OfficerSoldunder a preset trading plan
- Date
- 4 September 2026
- Shares
- 3,652
- Price
- $43.10
- Value
- $157,394
- Febbo Phillip G.Chief Scientific & Med OfficerSoldunder a preset trading plan
- Date
- 4 September 2026
- Shares
- 13,110
- Price
- $43.05
- Value
- $564,410
- Bhanji MunaDirectorSoldunder a preset trading plan
- Date
- 1 September 2026
- Shares
- 1,864
- Price
- $42.97
- Value
- $80,096
- EASTHAM KARINDirectorSoldunder a preset trading plan
- Date
- 18 June 2026
- Shares
- 3,729
- Price
- $52.89
- Value
- $197,224
- Leite JohnGlobal Chief Commercial OffSoldunder a preset trading plan
- Date
- 4 June 2026
- Shares
- 13,975
- Price
- $50.07
- Value
- $699,728
- McGuire AnnieEVP, General CounselSoldunder a preset trading plan
- Date
- 4 June 2026
- Shares
- 3,176
- Price
- $49.76
- Value
- $158,047
- Chambers RebeccaChief Financial OfficerSoldunder a preset trading plan
- Date
- 4 June 2026
- Shares
- 3,561
- Price
- $49.73
- Value
- $177,074
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 21 September 2026 | Leite John Global Chief Commercial Off | Sold under a preset trading plan | 4,015 | $40.00 | $160,600 |
| 14 September 2026 | Holstein Jens Director | Sold under a preset trading plan | 5,000 | $40.95 | $204,747 |
| 4 September 2026 | McGuire Annie EVP, General Counsel | Sold under a preset trading plan | 3,254 | $43.09 | $140,212 |
| 4 September 2026 | Chambers Rebecca Chief Financial Officer | Sold under a preset trading plan | 3,652 | $43.10 | $157,394 |
| 4 September 2026 | Febbo Phillip G. Chief Scientific & Med Officer | Sold under a preset trading plan | 13,110 | $43.05 | $564,410 |
| 1 September 2026 | Bhanji Muna Director | Sold under a preset trading plan | 1,864 | $42.97 | $80,096 |
| 18 June 2026 | EASTHAM KARIN Director | Sold under a preset trading plan | 3,729 | $52.89 | $197,224 |
| 4 June 2026 | Leite John Global Chief Commercial Off | Sold under a preset trading plan | 13,975 | $50.07 | $699,728 |
| 4 June 2026 | McGuire Annie EVP, General Counsel | Sold under a preset trading plan | 3,176 | $49.76 | $158,047 |
| 4 June 2026 | Chambers Rebecca Chief Financial Officer | Sold under a preset trading plan | 3,561 | $49.73 | $177,074 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.